Future perspective for potential Helicobacter pylori eradication therapies

Area of Science:

• Microbiology
• Gastroenterology
• Oncology

Background:

• Helicobacter pylori infection is a primary cause of chronic stomach inflammation.
• It is a significant risk factor for peptic ulcer disease and gastric cancer.
• Current triple or quadruple therapies for H. pylori eradication are facing declining efficacy.

Purpose of the Study:

• To review current progress in H. pylori therapeutics.
• To highlight alternative treatment options beyond standard antibiotic regimens.
• To focus on narrow-spectrum or nonantibiotic therapeutic strategies.

Main Methods:

• Literature review of recent research on H. pylori eradication.
• Analysis of studies focusing on novel vaccines and nonantibiotic agents.
• Evaluation of therapeutic options for both symptomatic and asymptomatic H. pylori carriers.

Main Results:

• Standard eradication therapies (acid suppressor + antibiotics +/- bismuth) show decreasing success rates.
• Antibiotic resistance in H. pylori strains is a growing concern.
• Development of H. pylori vaccines and alternative therapeutics is progressing.

Conclusions:

• There is an urgent need for novel H. pylori eradication strategies.
• Vaccines and nonantibiotic therapeutics offer promising alternatives to current treatments.
• Targeting H. pylori in asymptomatic carriers may help reduce gastric cancer incidence.